Literature DB >> 23937921

Mortality after septic versus aseptic revision total hip arthroplasty: a matched-cohort study.

Ho-Rim Choi1, Benjamin Beecher, Hany Bedair.   

Abstract

Mortality rates after revision total hip arthroplasty (THA) for periprosthetic sepsis were investigated in 93 patients and compared to 93 patients, matched for age, gender, year of surgery, who underwent revision for aseptic failures. The mortality rate was 33% (31/93) in the septic group and 22% (20/93) in the aseptic group at 5 and 6 year follow-up, respectively (P=0.10). Patients in the septic group died on average 6 years earlier (74 versus 80 yrs; P<0.05) than those in the aseptic group. Charlson Comorbidity Index (CCI) was an independent predictor of mortality among the both groups (P<0.05), while age (P<0.01) was a predictor of mortality only in the aseptic group. While revision THA for sepsis alone did not predict increased mortality, a 33% mortality rate at five years in patients with an average age of 66 years and earlier death by 6 years compared to aseptic revisions is alarming.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  mortality; septic revision; total hip arthroplasty

Mesh:

Year:  2013        PMID: 23937921     DOI: 10.1016/j.arth.2013.02.041

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  11 in total

1.  What is the Long-term Economic Societal Effect of Periprosthetic Infections After THA? A Markov Analysis.

Authors:  Thomas J Parisi; Joseph F Konopka; Hany S Bedair
Journal:  Clin Orthop Relat Res       Date:  2017-04-07       Impact factor: 4.176

2.  Topical adjuvants incompletely remove adherent Staphylococcus aureus from implant materials.

Authors:  Emily P Ernest; Anthony S Machi; Brock A Karolcik; Paul R LaSala; Matthew J Dietz
Journal:  J Orthop Res       Date:  2017-11-30       Impact factor: 3.494

3.  Editor's Spotlight/Take 5: Increased Mortality After Prosthetic Joint Infection in Primary THA.

Authors:  Seth S Leopold
Journal:  Clin Orthop Relat Res       Date:  2017-08-24       Impact factor: 4.176

4.  A History of Treated Periprosthetic Joint Infection Increases the Risk of Subsequent Different Site Infection.

Authors:  Hany Bedair; Nitin Goyal; Mathew J Dietz; Kenneth Urish; Viktor Hansen; Jorge Manrique; William Hamilton; Greg Deirmengian
Journal:  Clin Orthop Relat Res       Date:  2015-07       Impact factor: 4.176

5.  Increased Mortality After Prosthetic Joint Infection in Primary THA.

Authors:  Per Hviid Gundtoft; Alma Becic Pedersen; Claus Varnum; Søren Overgaard
Journal:  Clin Orthop Relat Res       Date:  2017-02-24       Impact factor: 4.176

6.  Risk factors for mortality following one-stage septic hip arthroplasty - a case-control study.

Authors:  Sophia-Marlene Busch; Mustafa Citak; Mustafa Akkaya; Felix Prange; Thorsten Gehrke; Philip Linke
Journal:  Int Orthop       Date:  2021-09-30       Impact factor: 3.075

7.  Rate of surface contamination in the operating suite during revision total joint arthroplasty.

Authors:  Matthew J Dietz; Phillip A Bostian; Emily P Ernest; Adam E Klein; P Rocco LaSala; Benjamin M Frye; Brock A Lindsey
Journal:  Arthroplast Today       Date:  2018-10-29

8.  Timing of hip hemiarthroplasty and the influence on prosthetic joint infection.

Authors:  Nolan S Horner; Kirsten M Grønhaug Larsen; Eleonor Svantesson; Kristian Samuelsson; Olufemi R Ayeni; Jan-Erik Gjertsen; Bengt Östman
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

9.  Chronic Periprosthetic Hip Joint Infection. A Retrospective, Observational Study on the Treatment Strategy and Prognosis in 130 Non-Selected Patients.

Authors:  Jeppe Lange; Anders Troelsen; Kjeld Søballe
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

Review 10.  Bisphosphonates for delivering drugs to bone.

Authors:  Shuting Sun; Jianguo Tao; Parish P Sedghizadeh; Philip Cherian; Adam F Junka; Esmat Sodagar; Lianping Xing; Robert K Boeckman; Venkatesan Srinivasan; Zhenqiang Yao; Brendan F Boyce; Brea Lipe; Jeffrey D Neighbors; R Graham G Russell; Charles E McKenna; Frank H Ebetino
Journal:  Br J Pharmacol       Date:  2021-04-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.